REGENXBIO Inc. (RGNX)

NASDAQ: RGNX · Real-Time Price · USD
7.34
-0.28 (-3.67%)
Dec 23, 2024, 11:04 AM EST - Market open
-3.67%
Market Cap 363.66M
Revenue (ttm) 84.33M
Net Income (ttm) -238.81M
Shares Out 49.55M
EPS (ttm) -5.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 414,798
Open 7.64
Previous Close 7.62
Day's Range 7.31 - 7.77
52-Week Range 7.21 - 28.80
Beta 1.24
Analysts Strong Buy
Price Target 36.00 (+390.46%)
Earnings Date Nov 6, 2024

About RGNX

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenn... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 17, 2015
Employees 344
Stock Exchange NASDAQ
Ticker Symbol RGNX
Full Company Profile

Financial Performance

In 2023, REGENXBIO's revenue was $90.24 million, a decrease of -19.94% compared to the previous year's $112.72 million. Losses were -$263.49 million, -6.00% less than in 2022.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for RGNX stock is "Strong Buy." The 12-month stock price forecast is $36.0, which is an increase of 390.46% from the latest price.

Price Target
$36.0
(390.46% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

NEW YORK , Dec. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of tr...

16 days ago - PRNewsWire

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

Alignment achieved with FDA on AFFINITY DUCHENNE® pivotal program and access to accelerated approval; BLA expected in 2026 Pivotal trial of RGX-202 is enrolling ambulatory patients aged 1 and above wi...

5 weeks ago - PRNewsWire

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

-       Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial and Michael Kelly, PhD, Chief Scientific Officer of CureDuchenne ROCKVILLE, Md.

5 weeks ago - PRNewsWire

REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript

REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript

6 weeks ago - Seeking Alpha

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

Advancement in Phase I/II AFFINITY DUCHENNE® trial of RGX-202 for Duchenne Muscular Dystrophy; pivotal trial initiation and first functional data expected this month BLA submission for RGX-121 initiat...

6 weeks ago - PRNewsWire

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md. , Nov. 4, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: UBS Global Healthcare Conference  Fireside Chat: ...

7 weeks ago - PRNewsWire

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

Positive updated long-term results from phase I/II/III CAMPSITE study using RGX-121 for the treatment of patients with MPS II. Rolling BLA submission of RGX-121 for the treatment of patients with MPS ...

7 weeks ago - Seeking Alpha

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

ROCKVILLE, Md. , Oct. 30, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, November 6, at 4:30 p.m.

7 weeks ago - PRNewsWire

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024

97% reduction in treatment burden at nine months after treatment with ABBV-RGX-314 Data consistent with that from multiple previous studies demonstrating favorable safety and efficacy profile Well tol...

2 months ago - PRNewsWire

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

ROCKVILLE, Md. , Oct. 18, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present new interim data evaluating subretinal delivery of ABBV-RGX-314 in patients with bilat...

2 months ago - PRNewsWire

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference

ROCKVILLE, Md. , Sept. 23, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8th Annual Genetic Medicines Conference on Monday, September 30, 2024.

3 months ago - PRNewsWire

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

Life sciences veteran Mitchell Chan joins the company ahead of multiple catalysts across late-stage gene therapy programs Vit Vasista steps down following more than 15 years at the Company ROCKVILLE, ...

3 months ago - PRNewsWire

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect

-  Data from pivotal dose level demonstrates long-term, sustained reductions in CSF levels of HS D2S6, a key biomarker of brain disease in MPS II -  80% of patients who received the pivotal dose disco...

3 months ago - PRNewsWire

REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

ROCKVILLE, Md. , Aug. 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hu...

4 months ago - PRNewsWire

REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

ROCKVILLE, Md. , Aug. 8, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the H.C.

4 months ago - PRNewsWire

Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder

Regenxbio Inc.'s rolling BLA submission of RGX-121 for the treatment of patients with MPS II expected in Q3 of 2024. Additional results from the phase 1/2/3 CAMPSIITE study, using RGX-121 for the trea...

4 months ago - Seeking Alpha

REGENXBIO Inc. (RGNX) Q2 2024 Earnings Call Transcript

REGENXBIO Inc. (NASDAQ:RGNX) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Patrick Christmas - CLO Curran Simpson - President and CEO Steve Pakola - CMO Vit Vasista ...

5 months ago - Seeking Alpha

REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights

Company remains on track for its first BLA filing in 2024 and is accelerating progress toward pivotal trial initiation for Duchenne (H2 2024) and diabetic retinopathy (H1 2025) New, positive data from...

5 months ago - PRNewsWire

REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202

Robust microdystrophin expression observed in new data from pivotal dose Patients aged 5.8 and 8.5 years at dosing had expression levels at 77.2% and 46.5% of control, respectively Consistent high exp...

5 months ago - PRNewsWire

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights

ROCKVILLE, Md. , July 25, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 1, 2024, at 4:30 p.m.

5 months ago - PRNewsWire

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients

Company to begin enrollment of  patients aged 1-3 years Expects data from younger cohort to be part of pivotal plans and BLA filing for broad label End-of-Phase II meeting with FDA scheduled for late ...

6 months ago - PRNewsWire

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II

Aligned with FDA on content of BLA and plans for submission: Submission of a rolling BLA using the accelerated approval pathway expected to start in Q3 2024 Confirmatory trial expected to begin in H2 ...

6 months ago - PRNewsWire

REGENXBIO Announces Leadership Transition

Curran Simpson, Chief Operating Officer, Appointed as President and CEO Co-Founder Kenneth T. Mills to Step Down as President and CEO; Named Chairman of the Board ROCKVILLE, Md.

6 months ago - PRNewsWire

Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy

REGENXBIO develops AAV therapies using its proprietary NAV platform, offering one-dose treatments targeting disease root causes. The company's pipeline includes promising candidates for age-related ma...

6 months ago - Seeking Alpha

REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

ROCKVILLE, Md. , June 5, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 202...

7 months ago - PRNewsWire